...disease-related pain after 50 of 380 planned patients had enrolled. JMAT then licensed satraplatin to NeoTherapeutics Inc....

...regained the program in 2003 after PanTherix did not fulfill diligence obligations. E. 10/1/02 - NeoTherapeutics...

...cancer (HRPC) in patients who have failed prior chemotherapy. GPC in-licensed satraplatin from SPPI (then NeoTherapeutics Inc....

...clinical development team, after which it in-licensed a Phase III cancer compound, satraplatin , from NeoTherapeutics Inc....

...Satraplatin .” In October 2002, GPC in-licensed satraplatin, an oral platinum therapy for cancer, from NeoTherapeutics Inc....
...$18.1M (PIPE) from Altana Clinical devt team from internal efforts 2002 Satraplatin from Spectrum (formerly NeoTherapeutics...
...$18.1M (PIPE) from Altana Clinical devt team from internal efforts 2002 Satraplatin from Spectrum (formerly NeoTherapeutics...

...III data at ASCO on its satraplatin oral platinum cancer therapy, which is partnered with NeoTherapeutics Inc....

...initial Phase II data in June for satraplatin , an oral platinum chemotherapeutic in-licensed from NeoTherapeutics...

...to investors about its new focus on satraplatin , an oral platinum chemotherapeutic in-licensed from NeoTherapeutics...

...effects associated with Ritalin. Data were presented at the Society for Neuroscience meeting in Orlando. NeoTherapeutics Inc....

...antipsychotic treatments. NEOT said both compounds had improved safety profiles compared to clozapine and risperidone. NeoTherapeutics Inc....